The Impact of Nucleotide Modifications on the Immune Responses of mRNA Vaccines

Yinuo Liu

doi:10.54097/bmddk068

Authors

Yinuo Liu

DOI:

https://doi.org/10.54097/bmddk068

Keywords:

mRNA vaccine, nucleotide modification, structural optimization, stability, translation efficiency.

Abstract

Messenger RNA (mRNA) vaccines play an important role in preventing infections and treating cancer. They offer notable advantages, including rapid design, flexible antigen encoding, and the feasibility of large-scale production. Despite these benefits, mRNA vaccines face some challenges, such as unintended immune activation, poor stability, and limited protein yield. Chemical modifications can help overcome these problems. Examples include N1-methylpseudouridine, 2’-O-methylation, and 5-methylcytidine. These changes improve stability and reduce immunogenicity. In addition, adjusting the 5' cap, controlling poly(A) tail length, and modifying untranslated regions (UTRs) can increase protein production and extend mRNA lifespan in the body. Together, these improvements increase antigen production, also strengthen immune responses against viruses, tumors, and chronic infections such as hepatitis B. Some challenges remain, like we need to know how modifications affect translation accuracy, how cells need different poly(A) lengths and UTRs, and how to combine cap changes with large-scale production. Addressing these problems is important to achieve safer and more effective mRNA therapies. This review summarizes current knowledge on nucleotide changes and design rules. It explains how they influence stability, translation efficiency, and immune activation, and offers advice on making the next generation of mRNA vaccines safer and more effective in clinical use.

Downloads

Download data is not yet available.

References

[1] Le T, Sun C, Chang J, et al. mRNA vaccine development for emerging animal and zoonotic diseases. Viruses, 2022, 14 (2): 401.

[2] Li Y, Wang M, Peng X, et al. mRNA vaccine in cancer therapy: current advance and future outlook. Clinical and Translational Medicine, 2023, 13 (8): e1384.

[3] Sittplangkoon C, Alameh MG, Weissman D, et al. mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model. Frontiers in Immunology, 2022, 13: 983000.

[4] Liu A, Wang X. The pivotal role of chemical modifications in mRNA therapeutics. Frontiers in Cell and Developmental Biology, 2022, 10: 901510.

[5] Gote V, Bolla PK, Kommineni N, et al. A comprehensive review of mRNA vaccines. International Journal of Molecular Sciences, 2023, 24 (3): 2700.

[6] Wang A Y L. Modified mRNA-based vaccines against coronavirus disease 2019. Cell Transplantation, 2022, 31: 9636897221090259.

[7] Kim SC, Sekhon SS, Shin WR, et al. Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency. Molecular & Cellular Toxicology, 2022, 18 (1): 1–8.

[8] Schoenmaker L, Witzigmann D, Kulkarni JA, et al. mRNA–lipid nanoparticle COVID-19 vaccines: structure and stability. International Journal of Pharmaceutics, 2021, 601: 120586.

[9] Wang C, Zhang Y, Dong Y. Lipid nanoparticle–mRNA formulations for therapeutic applications. Accounts of Chemical Research, 2021, 54 (23): 4283–4293.

[10] Li SH, Dong H, Li XF, et al. Rational design of a flavivirus vaccine by abolishing viral RNA 2′-O methylation. Journal of Virology, 2013, 87 (10): 5812–5819.

[11] Monroe J, Eyler DE, Mitchell L, et al. N1-methylpseudouridine and pseudouridine modifications modulate mRNA decoding during translation. Nature Communications, 2024, 15 (1): 8119.

[12] Feng J, Xu T, He M, et al. NSUN2-mediated m5C modification of HBV RNA positively regulates HBV replication. PLoS Pathogens, 2023, 19 (12): e1011808.

[13] Muttach F, Muthmann N, Rentmeister A. Synthetic mRNA capping. Beilstein Journal of Organic Chemistry, 2017, 13: 2819–2832.

[14] Linares-Fernández S, Lacroix C, Exposito JY, Verrier B. Tailoring mRNA vaccine to balance innate/adaptive immune response. Trends in Molecular Medicine, 2020, 26 (3): 311–323.

[15] Jin L, Zhou Y, Zhang S, Chen SJ. mRNA vaccine sequence and structure design and optimization: advances and challenges. The Journal of Biological Chemistry, 2025, 301 (1): 108015.

[16] Bollu A, Peters A, Rentmeister A. Chemo-enzymatic modification of the 5′ cap to study mRNAs. Accounts of Chemical Research, 2022, 55 (9): 1249–1261.

[17] Xu S, Yang K, Li R, Zhang L. mRNA vaccine era—mechanisms, drug platform and clinical prospection. International Journal of Molecular Sciences, 2020, 21 (18): 6582.

[18] Chen H, Liu D, Guo J, et al. Branched chemically modified poly (A) tails enhance the translation capacity of mRNA. Nature Biotechnology, 2025, 43 (2): 194–203.

[19] Li T, Liu G, Bu G, et al. Optimizing mRNA translation efficiency through rational 5′UTR and 3′UTR combinatorial design. Gene, 2025, 942: 149254.